Background
It has been hypothesised that the slow progression to AIDS exhibited by HLA-B*2705 + HIV-infected individuals is due to the immunodominant B*27-restricted response towards the p24 Gag epitope KK10 (Gag residues 263-272). This study aims to discern the contributing correlates of immune protection in HLA-B*2705 + HIV-infected individuals by comparing CD8 + T cell epitope specificity, cytokine profile, granzyme production and the kinetics of epitope presentation.
Methods
HLA-B*2705 MHC-I tetramers were used to enrich CD8 + T cell lines (>98% specific), specific for the Gag epitope KK10, the Vpr epitope VL9, and Pol epitope KY9. We compared the polyfunctionality, proliferation, granzyme production and specific killing capacity of these epitopespecific CD8+ T cells. We also compared the polyfunctionality and granzyme production of epitope-specific CD8 + T cells directly from ex vivo PBMCs. We then compared the ability of the different B*2705-restricted epitope specific CD8 + T cell lines (>98% specific) to suppress viral replication in vitro. HIV-permissive cells expressing B*2705 were infected and cocultured with the CD8 + T cells, firstly by synchronized magnetofection™ and monitored over 24 hours and secondly by 'natural' infection and monitored over 5-10 days.
Results
The Gag KK10-and Pol KY9-specific CD8 + T cells could elicit antiviral activity by 6 hours post-infection whereas the Vpr VL9-specific CD8 + T cells didn't elicit antiviral activity until 18 hours post-infection. We observed a clear hierarchy of antiviral potency dictated by epitope or HIV protein specificity (Gag KK10>Pol KY9>Vpr VL9). Antiviral activity did not correlate with polyfunctionality, proliferation, granzyme production or killing capacity.
Conclusion
The potent antiviral activity displayed by Gag KK10-specific CD8 + T cells may be due to early presentation of Gag epitopes on HIV-infected cells. A vaccine which promotes CD8 + T cells which can elicit early antiviral activity may help prevent viral dissemination during HIV infection and is a rational approach to vaccine design.
